Oncode Scientific Sdn Bhd
201501029484 (1154805-X)
Leading the Precision Medicine Revolution in Asia
Since 2015, Oncode Scientific Sdn Bhd has emerged as a trailblazer in the realm of precision medicine, setting new benchmarks in cancer molecular diagnostics. Our multidisciplinary team, comprising top-tier experts from molecular science and clinical practice, brings together decades of experience in medical diagnostics and research. At our cutting-edge facilities in Malaysia, we spearhead one of Asiaโs most pioneering precision medicine initiatives, specializing in both solid tumors and hematologic cancers. Our relentless pursuit of innovation drives us to constantly challenge the status quo, exceeding clinical and diagnostic standards to deliver groundbreaking medical solutions. Oncode is dedicated to transforming healthcareโadvancing disease prevention, early detection, and targeted intervention. With a commitment to excellence, we provide world-class molecular diagnostic services that are both accessible and revolutionary, empowering the global community to embrace the full potential of precision medicine.
07/04/2026
On World Health Day 2026, the global focus is clear:
๐ง๐ผ๐ด๐ฒ๐๐ต๐ฒ๐ฟ ๐ณ๐ผ๐ฟ ๐๐ฒ๐ฎ๐น๐๐ต. ๐ฆ๐๐ฎ๐ป๐ฑ ๐๐ถ๐๐ต ๐ฆ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ.
As healthcare challenges continue to evolve, the role of science has never been more critical. From preventive medicine to personalised treatment strategies, evidence-based innovation is at the core of better health outcomes.
Advancements in diagnostics, genomics, and precision medicine are reshaping how we understand, prevent, and manage disease โ enabling a shift toward more proactive and individualised care.
At the same time, meaningful progress requires collective effort โ across healthcare systems, professionals, and communities.
Health is not built in isolation.
It is shaped through collaboration, guided by science, and strengthened by informed action.
If you're excited about genomics, innovation, and making real clinical impact, weโd love to hear from you.
01/04/2026
When every genomic insight can change a treatment path, ๐บ๐ถ๐๐๐ถ๐ป๐ด ๐ฎ ๐บ๐๐๐ฎ๐๐ถ๐ผ๐ป ๐ถ๐ ๐ป๐ผ๐ ๐ฎ๐ป ๐ผ๐ฝ๐๐ถ๐ผ๐ป.
On 26 March 2026, Oncode engaged with the ๐๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐ ๐๐ฒ๐ฝ๐ฎ๐ฟ๐๐บ๐ฒ๐ป๐ ๐ฎ๐ ๐จ๐ป๐ถ๐๐ฒ๐ฟ๐๐ถ๐๐ ๐ ๐ฎ๐น๐ฎ๐๐ฎ ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ฎ๐น ๐๐ฒ๐ป๐๐ฟ๐ฒ (๐จ๐ ๐ ๐) on how ๐บ๐ผ๐น๐ฒ๐ฐ๐๐น๐ฎ๐ฟ ๐ฑ๐ถ๐ฎ๐ด๐ป๐ผ๐๐๐ถ๐ฐ๐ ๐ฎ๐ฟ๐ฒ ๐ฟ๐ฒ๐๐ต๐ฎ๐ฝ๐ถ๐ป๐ด ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฐ๐ฎ๐ฟ๐ฒ.
The discussion centred on a key priority โ ๐ถ๐บ๐ฝ๐ฟ๐ผ๐๐ถ๐ป๐ด ๐๐ต๐ฒ ๐ฑ๐ฒ๐๐ฒ๐ฐ๐๐ถ๐ผ๐ป ๐ผ๐ณ ๐ฎ๐ฐ๐๐ถ๐ผ๐ป๐ฎ๐ฏ๐น๐ฒ ๐บ๐๐๐ฎ๐๐ถ๐ผ๐ป๐ ๐๐ผ ๐๐๐ฝ๐ฝ๐ผ๐ฟ๐ ๐ฏ๐ฒ๐๐๐ฒ๐ฟ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐ฑ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป๐. Through our ๐ก๐๐ฆ ๐ฎ๐ป๐ฑ ๐ฃ๐๐ฅ ๐ฝ๐ฎ๐ป๐ฒ๐น๐, we deliver ๐ฐ๐ผ๐บ๐ฝ๐ฟ๐ฒ๐ต๐ฒ๐ป๐๐ถ๐๐ฒ, ๐ต๐ถ๐ด๐ต-๐พ๐๐ฎ๐น๐ถ๐๐ ๐บ๐ผ๐น๐ฒ๐ฐ๐๐น๐ฎ๐ฟ ๐ฝ๐ฟ๐ผ๐ณ๐ถ๐น๐ถ๐ป๐ด that supports confident, precision-driven decisions in clinical practice.
From ๐ฟ๐ถ๐ด๐ผ๐ฟ๐ผ๐๐ ๐๐ฎ๐น๐ถ๐ฑ๐ฎ๐๐ถ๐ผ๐ป to ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น๐น๐ ๐ฎ๐ฐ๐๐ถ๐ผ๐ป๐ฎ๐ฏ๐น๐ฒ ๐ฟ๐ฒ๐๐๐น๐๐, quality isnโt just a benchmark โ itโs our responsibility to every patient.
The session sparked valuable conversations on ๐ถ๐ป๐๐ฒ๐ด๐ฟ๐ฎ๐๐ถ๐ป๐ด ๐บ๐ผ๐น๐ฒ๐ฐ๐๐น๐ฎ๐ฟ ๐๐ฒ๐๐๐ถ๐ป๐ด ๐ถ๐ป๐๐ผ ๐ฟ๐ผ๐๐๐ถ๐ป๐ฒ ๐ผ๐ป๐ฐ๐ผ๐น๐ผ๐ด๐ ๐๐ผ๐ฟ๐ธ๐ณ๐น๐ผ๐๐, reinforcing a shared direction:
๐ฝ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป, ๐ฐ๐ผ๐น๐น๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ถ๐ผ๐ป, ๐ฎ๐ป๐ฑ ๐ฏ๐ฒ๐๐๐ฒ๐ฟ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐ ๐ผ๐๐๐ฐ๐ผ๐บ๐ฒ๐.
Thank you to the UMMC team for the meaningful exchange.
30/03/2026
๐๐ผ๐น๐ผ๐ฟ๐ฒ๐ฐ๐๐ฎ๐น ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ is increasingly being diagnosed at younger ages โ often without obvious early warning signs.
While symptoms may appear subtle, risk can be present long before they surface. This is why screening, and in some cases genetic evaluation, plays a critical role in early detection and prevention.
Understanding your ๐ถ๐ป๐ฑ๐ถ๐๐ถ๐ฑ๐๐ฎ๐น ๐ฟ๐ถ๐๐ธ ๐ฝ๐ฟ๐ผ๐ณ๐ถ๐น๐ฒ โ including family history and genetic predisposition โ enables a more proactive and personalised approach to care.
Early detection does not only improve outcomes.
It changes them.
๐ฉบ If you fall within a ๐ต๐ถ๐ด๐ต๐ฒ๐ฟ-๐ฟ๐ถ๐๐ธ ๐ด๐ฟ๐ผ๐๐ฝ or have concerns about your health, consider speaking to a healthcare professional about appropriate screening and testing options.
20/03/2026
๐๏ธ Hari Raya is a time of reflection, forgiveness, and renewal.
As we welcome the blessed month of Syawal, we extend our heartfelt wishes to all who celebrate. Selamat Hari Raya, Maaf Zahir dan Batin.๐ฟ
May this festive season bring you closer to your loved ones and fill your days with joy, peace, and meaningful moments together. May the spirit of Aidilfitri inspire renewed strength, gratitude, and harmony in the days ahead.
19/03/2026
Genetic testing plays an important part in how we understand health, risk, and treatment today.
From identifying inherited risks to guiding cancer care and monitoring disease, genetic insights are helping doctors make more informed, personalized decisions.
But many questions still remain:
Who should get tested?
What can it really tell you?
And just as importantโwhat canโt it tell you?
Understanding these answers is the first step toward making better health decisionsโfor yourself and your family.
Explore the essentials of genetic testing through our Q&A series.
07/03/2026
Understanding your cancer risk starts with knowing when to test.
Many cancers develop silently โ long before symptoms appear. Genetic testing and appropriate screening can help identify risk earlier, allowing doctors to monitor, prevent, or treat cancer more effectively.
Genetic testing may be recommended if you have a personal or family history of cancer, known genetic mutations in the family, or other factors that may increase your risk.
In todayโs era of precision medicine, understanding your genetic profile provides valuable insight for early detection, personalised prevention strategies, and more informed healthcare decisions.
Because when it comes to cancer, knowing your risk is the first step toward protecting your health.
If youโre unsure whether genetic testing is right for you, consider speaking with a healthcare professional to explore your options.
06/03/2026
On 12 February, we engaged with the Respiratory Medicine and Laboratory teams at Hospital Raja Permaisuri Bainun for a CME session on the pivotal role of Next Generation Sequencing (NGS) in personalised Non-Small Cell Lung Cancer (NSCLC) care.
The session explored the fundamentals of NGS testing and how genomic biomarkers increasingly shape diagnostic pathways and treatment strategies. Discussions highlighted how comprehensive and sensitive molecular insights can support clinicians in selecting more targeted and personalised therapies for their patients.
Beyond the technology itself, the session also emphasised the importance of best-practice pre-analytical sample handling and preparation, as these critical steps directly influence the accuracy and reliability of NGS results. Strong coordination between clinicians and laboratory teams remains essential to ensure high-quality testing and meaningful clinical interpretation.
As oncology continues to advance towards precision-driven care, close collaboration between diagnostics and clinical teams is key to translating molecular insights into better-informed treatment decisions for patients.
05/03/2026
We were honoured to be invited by the Clinical Haematology team at Hospital Pakar PUSRAWI Kuala Lumpur to deliver a lecture on the evolving role of Next Generation Sequencing (NGS) in the diagnostic and therapeutic management of acute leukaemia.
The session explored how molecular profiling technologies, particularly PCR and NGS, complement each other in the assessment of blood cancers. Through this discussion, clinicians examined how the depth and breadth of genomic information can support more informed diagnostic and treatment decisions in acute leukaemia.
Our consultant pathologist, Dr. Subramanian Yegappan, shared expert insights on Acute Myeloid Leukaemia (AML) mutation and fusion testing, highlighting their clinical relevance and how molecular findings guide therapeutic strategies. The discussion also emphasised the importance of rapid turnaround time when determining the presence or absence of mutations and fusions, as timely molecular information is often critical for initiating the most appropriate treatment.
Real clinical case studies further illustrated how molecular monitoring plays a vital role in managing AML, reinforcing the importance of integrating genomic data into routine haematology practice.
As precision haemato-oncology advances, timely and accurate molecular insights remain essential in guiding diagnosis, prognostication, treatment, and ongoing disease management.
04/03/2026
Advancing cancer care starts with understanding the full molecular picture.
At our recent CME session, we discussed how comprehensive genomic profiling is reshaping modern oncology practice. Real-world data continue to show that tumors are molecularly complex โ often harbouring multiple, co-existing, or uncommon alterations that can influence prognosis, resistance, and treatment strategy.
While PCR remains fast and cost-effective, it is inherently targeted โ detecting only predefined mutations. Rare variants, complex alterations, and changes outside hotspot regions may go undetected.
In todayโs era of precision oncology, what we donโt test for, we donโt find. Broader genomic testing empowers more informed decisions โ and ultimately, more personalized cancer care.
03/03/2026
Precision oncology continues to evolve โ and so must the way we test.
In this session, we examined the complementary roles of PCR and NGS technologies in molecular profiling, particularly in lung cancer, where testing strategy directly shapes diagnostic accuracy and targeted treatment decisions. While PCR offers speed and cost efficiency, comprehensive NGS profiling provides broader genomic insight โ enabling clinicians to detect actionable alterations that may otherwise remain unseen.
We also introduced our expanded NGS & PCR panels designed to support clinical applications across lung, breast, colon, ovarian, endometrial, prostate, gastric, and all other solid tumours.
Beyond technology, the discussion reinforced the importance of stringent validation processes and robust quality control frameworks to uphold high standards of sensitivity and precision in NGS testing. We also shared updates on our subsidised diagnostic support programmes, alongside the expanding role of both tissue and liquid biopsy applications in delivering comprehensive cancer care.
As oncology becomes increasingly molecular, broader genomic testing empowers more informed decisions โ and ultimately, more personalised treatment strategies.
28/02/2026
An engaging afternoon at the Oncology Department of Hospital Pulau Pinang brought together 18 oncology professionals to examine how NGS is reshaping clinical decision-making in cancer care.
๐ง๐ต๐ถ๐ ๐๐ฒ๐๐๐ถ๐ผ๐ป ๐ฒ๐ ๐ฝ๐น๐ผ๐ฟ๐ฒ๐ฑ:
โช๏ธHow comprehensive genomic profiling identifies various actionable genomic alterations and genomic signatures in a single assay
โช๏ธThe role of NGS results in guiding targeted therapy selection, immunotherapy considerations, and clinical trial matching
โช๏ธWhy early and appropriate integration of NGS optimises treatment strategies, reduces ineffective interventions, and improves patient outcomes
๐ฌPrecision oncology is not defined by complexity โ but by clarity. The right genomic insight at the right time changes the treatment trajectory.
Thank you to all participants for advancing evidence-based, personalised cancer care together.
Address
Lot 03-01, 3rd Floor. Hap Seng Business Park, No. 12, Persiaran Perusahaan, Unity Square. Seksyen 23, Shah Alam D. E. Shah Alam 40300
Be the first to know and let us send you an email when Oncode Scientific Sdn Bhd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
ONCODE Scientific Sdn Bhd was founded in 2015, by a strong knowledge-based management and operational team with the combination of more than 85 years of experience in the areas of medical diagnostics and scientific research. Itโs aims to be a niche player specializing in Precision Medicine utilizing the techniques of Next Generation Sequencing (NGS), Sanger sequencing, Real-Time & Standard PCR technologies. The team comprises of scientists, geneticists, physicians, pharmacists, bioinformaticians and business veterans who aim to deliver the best quality and affordable molecular diagnostic solutions to the global community.
Oncode laboratory workflows and pipelines include internal and external validation quality controls for compliance with international standards of Good Laboratory Practice (GLP), ISO 15189, the Association for Molecular Pathology (AMP) and the College of American Pathologist (CAP).
The laboratory participates in external quality assurance and proficiency programs including the UK National External Quality Assurance System (UKNEQAS), The European Molecular Genetics Quality Network (EMQN) and the Royal College of Pathologists of Australasia (RCPA).
Oncode Mission
To provide quality diagnostic solutions to customers through the implementation of state-of-the-art laboratory setup designed to worldwide standards, recruitment of dedicated professionals and comprehensive reporting systems.
Oncode Objective
To be a regional one-stop molecular genetics solution center, delivering powerful diagnostic support and insight to medical professionals
